Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
- Associated Therapies
- -
Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 1197
- Registration Number
- NCT01018160
An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 217
- Registration Number
- NCT01008696
A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00999128
- Locations
- 🇺🇸
Genentech Trial Information Support, South San Francisco, California, United States
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
- Conditions
- Interventions
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT00911534
A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00855361
Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 120
- Registration Number
- NCT00844675
- Locations
- 🇰🇷
Catholic University, Gangnam St. Mary's Hospital, Seoul, Ban-po dong 505, Korea, Republic of
Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers
- Conditions
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 106
- Registration Number
- NCT00838682
- Locations
- 🇰🇷
Bucheon St. Mary's Hospital, Bucheon, Kyungkido, Korea, Republic of
🇰🇷Uijeongbu St.Mary's Hospital, Uijeongbu, Kyungkido, Korea, Republic of
A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2013-01-24
- Target Recruit Count
- 127
- Registration Number
- NCT00787891
A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive
- Conditions
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2011-01-10
- Target Recruit Count
- 31
- Registration Number
- NCT00747695
A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 178
- Registration Number
- NCT00681005
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.